TUCSON, AZ - 10/28/2016 (PRESS RELEASE JET)
On Saturday October 29 World Psoriasis Day gives voice to the 125 million people worldwide with psoriasis/psoriatic arthritis. Organized by the International Federation of Psoriasis Association, the event’s theme aim is to fight prejudice, exclusion, discrimination, stigma and bullying that psoriasis patients often encounter.
Psoriasis is a non-infectious autimmune condition where skin cells grow rapidly and form into plaques that can be unsightly and uncomfortable. Around3% of the population is affected by psoriasis.
CTX Technology is developing a topical treatment for plaque psoriasis, one we hope will provide lasting clearance of symptoms for the over 80% of patients who suffer from mild-to-moderate psoriasis. Current topical treatments have limited effectiveness and must be rotated because of damage to the skin that can occur with prolonged use.
The CTX Technology team looks forward to the day when all mild-to-moderate psoriasis patients can achieve lasting clearance of their plaque and enjoy improved quality of life.
About CTX Technology
CTX Technology, a virtual company headquartered in Tucson, Arizona, is an early-stage biopharmaceutical company engaged in preclinical activities. Utilizing a proprietary technology licensed from the University of California Santa Barbara, CTX is developing a formulation of cyclosporine for topical use by patients suffering from mild-to-moderate plaque psoriasis. A cell-penetrating peptide is used to carry cyclosporine through the outer barrier layer of the skin and into the layer of the skin where it can shut down the autoimmune response that drives psoriasis. By delivering the cyclosporine in a localized fashion, CTX expects that the adverse effects of cyclosporine can be minimized or completely eliminated. With renowned MIT scientist Robert S. Langer as an advisor and a team that includes Mark Dahl, former head of dermatology at the Mayo Clinic, and Betty Yu, formerly VP Skin and New Materials Discover, Living Proof, Inc., CTX expects to complete a proof-of-concept early in 2017, demonstrating the effectiveness of topical delivery of cyclosporine. CTX is currently in discussion with partners and investors to secure the resources required to bring the topical cyclosporine product into clinical trials.
|person_outline||Full Name:||David Loynd, President & CEO|
|phone||Phone Number:||(844) 208-0815|
|business_center||Company:||CTX Technology Inc.|
|mail_outline||Email: Send Email|